BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

On November 6, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), reported preclinical findings from four posters at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations highlight BriaCell’s Bria-OTS+ off-the-shelf cellular immunotherapy platform and BriaPro’s BP-80 and TILsRx immunotherapy programs, including advances in engineered CD80 proteins.

"These findings provide additional preclinical support for our cellular immunotherapy and checkpoint inhibitor programs, including Bria-BRES+ in breast cancer and Bria-PROS+ in prostate cancer," stated William V. Williams, MD, BriaCell’s President and CEO. "The results support continued development of our immunotherapy pipeline across multiple cancer indications."

Highlights of the SITC (Free SITC Whitepaper) 2026 Presentations

BriaCell

Title: A Multifaceted Genetically Engineered Whole-Cell Vaccine Platform Generates Potent, Broad, Persistent, and Effector-Centric Anti-Tumor Immunity Across Multiple Cancer Indications
Abstract Number: 863
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Friday, Nov. 6, 2026
Time: 12:15 – 1:45 PM, 5:30 – 7:00 PM MT

Key Findings:
Bria-OTS+ demonstrated broad innate and adaptive immune activation, including stimulating immune cells from patients with breast and prostate cancer. Priming and boosting enhanced cancer-cell killing across multiple tumor cell lines, while repeated tumor challenges demonstrated sustained cytotoxic activity. Activity was also confirmed in Bria-OTS+-activated immune cells derived from cancer patients.

BriaPro

Title: Development of BP-80, a soluble CD80 dimer (CD80-Fc) for cancer treatment
Abstract Number: 404
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Saturday, Nov. 7, 2026
Time: 12:00 – 1:30 PM, 6:40 – 8:10 PM MT

Key Findings:
BP-80 demonstrated CD28 co-stimulatory activity and counteracted CTLA-4-mediated inhibition in cell-based assays. In a four-week GLP nonhuman primate study, BP-80 was well tolerated, with no treatment-related pathological findings and a No Observed Effect Level (NOEL) of 50 mg/kg/dose, well above the predicted clinically active dose.

Title: Tumor-targeted checkpoint inhibitors for reactivation of tumor-infiltrating lymphocytes
Abstract Number: 405
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Friday, Nov. 6, 2026
Time: 12:15 – 1:45 PM, 5:30 – 7:00 PM MT

Key Findings:
TILsRx-001, a B7-H3-targeting TILsRx construct with two CD80 extracellular domains (ECD), antagonized the immune inhibitory effect of PD-L1 in a cell-based surrogate assay. Engineered with two mutations in each CD80 ECD, TILsRx-001 demonstrated a 49-fold higher binding affinity for PD-L1 than the corresponding TILsRx construct without these CD80 mutations, supporting further development of TILsRx-001 as a tumor-targeted checkpoint inhibitor.

Title: Molecular design of CD80 variants with increased affinity for PD-L1 and wild-type or lower affinity for CD28
Abstract Number: 406
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Saturday, Nov. 7, 2026
Time: 12:00 – 1:30 PM, 6:40 – 8:10 PM MT

Key Findings:
Structure-guided engineering generated a soluble CD80 variant (CD80-Fc) with more than 130-fold stronger PD-L1 binding than CD80-Fc with wild-type CD80 sequence. Multiple CD80 mutations enhanced PD-L1 binding with no or only minimal effect on CD28 affinity, supporting the development of CD80-based immunotherapies.

Following the presentation, copies of the posters will be made available at View Source

(Press release, BriaCell Therapeutics, NOV 6, 2026, View Source [SID1234674422])

Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026

On November 6, 2026 Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics ("Molecular Partners" or the "Company"), reported the presentation of new preclinical data supporting an attractive therapeutic window for MP0632, a logic-gated Switch-DARPin T cell engager (TCE) with integrated CD2 co-stimulation, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These new data highlight that our logic-gated Switch-DARPin TCEs can address one of the central challenges in solid tumors: achieving potent anti-tumor activity while avoiding side-effects on healthy tissues that express the same targets. The clean in situ safety data on primary mesothelial cells and lung pleura is compelling and exactly the kind of evidence we need to support advancing MP0632 into IND-enabling studies in cancer indications co-expressing MSLN and EpCAM," said Martin Steegmaier, Ph.D., Chief Scientific Officer of Molecular Partners. He added: "These new data validate the potential of the Switch-DARPin platform to unlock tumor antigens so-far considered undruggable."

The SITC (Free SITC Whitepaper) poster outlines the following key findings:

Potent and selective tumor cell killing, with efficacy comparable to a clinical-stage benchmark T-cell engager but a substantially improved safety profile
Safe integration of CD2 co-stimulation, enabling sustained T-cell activity
No detectable impact on primary human mesothelial or epithelial cells and no evidence of mononuclear cell infiltration in the lung pleura of mice expressing human EpCAM and MSLN

These data provide preclinical proof-of-concept that logic-gated Switch-DARPins can selectively target TAAs considered undruggable for TCEs to date, turning MSLN and EpCAM into a "clean" target pair. These results build on previously presented data demonstrating regression of established tumors expressing both EpCAM and MSLN, with minimal impact on tissue expressing only one antigen. In addition, the Switch-DARPin design allowed for safe use of potent co-stimulation for efficient tumor cell killing with low cytokine release profile.

Taken together, the preclinical data support advancing MP0632 into IND-enabling studies for solid tumors co-expressing MSLN and EpCAM, such as ovarian, endometrial, lung and pancreatic cancers.

Molecular Partners explores the broad therapeutic potential of its DARPin platforms, including Switch-DARPins inside and outside of oncology, through strategic partnerships and platform-derived spin-out opportunities, representing potential upside beyond its strategic focus on radiotherapeutics.

Details of the presentation

Title: MP0632, a logic-gated conditional Switch-DARPin T cell engager with CD2 co-stimulation enabling selective activity against solid tumors co-expressing MSLN and EpCAM
Poster #1072, a Top 150 SITC (Free SITC Whitepaper) 2026 Abstract
Date & Time: 07 Nov 2026; 12:30-1:30 and 6:40-8:10 pm MT (poster viewing times)
Location: Phoenix Convention Center (PCC) – North Building – Lower-Level- Exhibition Halls 4-6

SITC takes place November 4-8 in Phoenix, AZ, USA.
The poster will be made available on Molecular Partners’ website after the presentation.

About MP0632

MP0632 is a next-generation, logic-gated T cell engager designed to activate T cells only when both MSLN and EpCAM are present. Its Switch-DARPin design enables reversible, dual-target-dependent un-masking of the CD3 binder for tumor-localized efficacy, while avoiding systemic T cell activity and limiting impact on healthy tissues. The built-in CD2 co-stimulation maintains potent and sustained tumor-localized T cell function.

(Press release, Molecular Partners, NOV 6, 2026, View Source [SID1234674407])

SOTIO Presents Initial Data from VICTORIA-01 Phase 1 Clinical Study of Immunocytokine SOT201 at SITC Annual Meeting

On November 6, 2026 SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, reported interim safety and efficacy results from the VICTORIA-01 Phase 1 clinical study of SOT201, a PD-1 targeting IL-15 immunocytokine, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting taking place November 6-8, 2026, in Phoenix, AZ.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interim Phase 1 VICTORIA-01 data showed a 59% disease control rate with SOT201 among 22 patients with advanced solid tumors who had received a median of three prior treatment lines. Two patients achieved confirmed partial responses following prior checkpoint inhibitor therapy: an esophageal cancer response lasting 388 days and a cervical cancer response ongoing at 87 days. Most treatment-related adverse events were Grade 1 or 2. The findings supported a recommended dose of 80 µg/kg with a 20 µg/kg priming dose for further evaluation.

"Both IL-15 agonism and PD-1 inhibition have robust clinical validation in immuno-oncology, and SOT201 builds on this foundation by combining PD-1 and IL-15 mechanisms to reinvigorate antitumor T cell activities and to elicit deep antitumor immune responses," said Vivi Boura, M.D., Ph.D., chief medical officer of SOTIO. "These initial clinical data support continued evaluation of SOT201 in expanded patient cohorts, and we look forward to further characterizing its potential in challenging solid tumor types."

Presentation details are as follows:

Poster Title: "Interim safety and efficacy results of VICTORIA-01: A phase 1 study to evaluate the safety and preliminary efficacy of SOT201 in patients with advanced/metastatic solid tumors"
Poster Number: 1180
Presenter: Dr. Aung Naing, Department of Investigational Cancer Therapeutics, UT MD Anderson Cancer Center, Houston, Texas
Date: Saturday, Nov. 7, 2026

In additional poster presentations at SITC (Free SITC Whitepaper), SOTIO will share research on the localization of tertiary lymphoid structures (TLS) in immune checkpoint-resistant cancer types, as well as the role of PD-L1+ macrophages in shaping TLS organization in ovarian cancer metastases.

(Press release, SOTIO, NOV 6, 2026, View Source [SID1234674423])

New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

On November 6, 2026 Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology platform, reported new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 in patients with advanced melanoma (skin cancer).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data demonstrate potent EVX-01 induced immune responses and further underline the strong predictive performance of Evaxion’s AI-Immunology platform. It will be presented in both an oral and a poster session today and tomorrow respectively at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting, taking place in Phoenix, Arizona.

"It is exciting to announce yet another set of new and promising data providing insights into the magnitude, quality and systemic impact of EVX-01-induced immunity in advanced melanoma. The data provide a clear demonstration of the very strong immune responses induced by EVX-01 and also validates our AI-Immunology platform further. We are looking forward to sharing and discussing this data with both scientific stakeholders and potential business partners at the important SITC (Free SITC Whitepaper) meeting", says Birgitte Rønø, CSO and COO of Evaxion.

Comprehensive data package
The new data adds to EVX-01’s already comprehensive data package which includes three-year clinical response and immune data presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 held in October. These data showed 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in the phase 2 trial.

New findings include detection of EVX-01 induced neoantigen-specific T-cells directly ex vivo, which is a clear testament to the magnitude of the vaccine-induced immune responses. Ex vivo responses were dominated by CD4+ T-cells, while CD8+ T-cell responses were observed in half of patients.

The data also documents a significant association (p<0.001) between predictions by AI-Immunology and actual T-cell responses, confirming the strong predictive performance of the platform. Essentially, the platform predicts, with very high precision, which neoantigens will illicit the strongest immune responses allowing for selection of these as optimal vaccine targets.

SITC oral and poster presentation details:

Abstract title: EVX-01 personalized AI-designed vaccine plus pembrolizumab induce neoantigen-specific T-cell responses and systemic immune modulation in advanced melanoma
Abstract#: 502
Oral presentation:

Session: 105b: Rapid Oral – Clinical 1
Location: Phoenix Convention Center, West Building-300 Level – 301BC
Date/Time: Friday, November 6, 2026, 12:30-1:30pm MT / 20.30-21.30 CET
Presenter: Mads Lausen, Senior Scientist at Evaxion
Poster presentation:

Session: Poster Session
Location: Phoenix Convention Center, North Building-Lower Level – Exhibition Halls 4-6
Date/Time: Saturday, November 7, 2026, 12:30-1:30pm & 6:40-8:10pm MT / 20:30-21:30 CET & 02:40-04:10 CET (Sunday, November 8)
Presenter: Mads Lausen, Senior Scientist at Evaxion
About the phase 2 trial
The phase 2 trial investigated EVX-01 in patients with advanced melanoma (skin cancer). Each patient enrolled in the trial received a unique vaccine designed with Evaxion’s AI-Immunology prediction platform and manufactured based on their individual biology.

At two-year follow-up, the trial demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. Clinical and T-cell responses were sustained at three-year follow-up. 89% of the EVX-01 neoantigen targets triggered a tumor-specific immune response in the patients.

In the first two-years, patients received EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA (pembrolizumab). In the third year, a subset of patients received EVX-01 as stand-alone therapy. KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About EVX-01
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancer tumors. It is currently being evaluated as a treatment of advanced melanoma and is Evaxion’s lead clinical asset.

Designed with our AI-Immunology platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system by mounting a targeted response against tumor-specific neoantigens.

(Press release, Evaxion, NOV 6, 2026, View Source [SID1234674390])

Xspray Pharma publishes Interim Report for the third quarter 2026

On November 6, 2026 Xspray Pharma reported Interim results for the third quarter 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

July–September 2026, Group

Net sales amounted to SEK 0 thousand (0)
Earnings before tax amounted to SEK -39,323 thousand (-47,332)
Earnings per share before dilution amounted to SEK -0.83 (-1.25)
Cash flow from operating activities amounted to SEK -33,374 thousand (-41,354)
Cash flow from investing activities amounted to SEK -5,616 thousand (-6,865)
January–September 2026, Group

Net sales amounted to SEK 0 thousand (0)
Earnings before tax amounted to SEK -114,497 thousand (-134,537)
Earnings per share before dilution amounted to SEK -2.54 (-3.60)
Cash flow from operating activities amounted to SEK -100,996 thousand (-151,793)
Cash flow from investing activities amounted to SEK -16,990 thousand (-27,698)
Amounts in parentheses refer to the year-earlier period.

Significant events during the quarter

In August, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Xspray Pharma’s New Drug Application (NDA) for Dasynoc. The CRL relates to the previously communicated GMP observations at the third-party manufacturer NerPharMa, as well as a request for additional commercial scale consecutive batch data following already implemented corrective actions. The FDA did not raise questions regarding the clinical data, bioequivalence or stability of Dasynoc, and the risk of medication error raised in previous CRLs has been resolved. Xspray Pharma intends to resubmit the application during Q4 2026 after which a new PDUFA date will be issued.
In September, Xspray Pharma announced that data for Dasynoc and Nilopki had been accepted for poster presentation at the ESH-iCMLf 28th Annual John Goldman Conference on Chronic Myeloid Leukemia in Gothenburg on October 2–4, 2026. The data show significantly more consistent drug exposure with Dasynoc and a significantly lower food effect with Nilopki strengthening their clinical differentiation.
Significant events after the quarter

In October, Xspray Pharma announced that the FDA has confirmed that the NDA for Dasynoc can be resubmitted independently of NerPharMa’s cGMP status, as was previously confirmed for Nilopki. The company maintains its plan to resubmit both applications during Q4 2026, and manufacturing of the required additional commercial batches has commenced. Final regulatory clearance of the facility is still required before approval.
On 5 November, Xspray was informed that the FDA had initiated an unannounced follow-up inspection at NerPharMa’s manufacturing facility, relating to previously identified cGMP-observations.
After the period, the company announced that the Board had decided to carry out a rights issue of shares of approximately SEK 90 million, with preferential rights for the company’s existing owners. The rights issue can be increased by up to SEK 72 million through an over-allotment option. The company has also entered into an agreement with the lender to extend the maturity of its existing loan to 15 August 2028 and, following a contractual repayment, reduce the loan facility to SEK 50 million. The warrants held by the lender, which were issued in spring 2026, will be cancelled and replaced with newly issued warrants in connection with the loan extension.
A message from the CEO
The third quarter was an important period for Xspray Pharma, marked by continued regulatory clarity, disciplined financial management and further strengthening of the clinical and commercial rationale for our two lead product candidates, Dasynoc and Nilopki. While the quarter included a further regulatory delay for Dasynoc, our overall position has continued to develop in a constructive way. We have clarified the remaining regulatory path for both Dasynoc and Nilopki, continued to advance the activities required for resubmission of both NDAs, maintained our commercial readiness. After the end of the period, we were informed that the FDA had initiated a follow-up inspection at NerPharMa’s manufacturing facility, relating to previously identified cGMP-observations. The inspection is an important step in the ongoing regulatory processes for Dasynoc and Nilopki. We have also presented financing solutions aimed at securing funding through to the expected approvals of our two lead candidates.

Our strategic objective remains unchanged: to bring improved formulations of well-established and widely used oncology medicines to patients and to build Xspray into a commercial-stage oncology company. Dasynoc and Nilopki are the first two products in this strategy, each addressing distinct treatment needs within chronic myeloid leukemia, CML, where there is an established treatment market, a concentrated specialist prescriber base and clear clinical needs related to tolerability, exposure predictability, drug interactions, practical use over long treatment durations and better quality of life aspects for the patients.

Regulatory progress and path to resubmission
Dasynoc remains our near-term priority. During the quarter, Xspray received a Complete Response Letter from the FDA for Dasynoc. The FDA did not raise questions regarding the clinical data, bioequivalence or stability, and the risk of medication error raised in previous review cycles has thus been resolved. We have addressed this question over several review cycles through adjusted tablet strengths and labeling comprehension work, and we are pleased to have it closed. The remaining issues concern supporting batch data and the cGMP status of NerPharMa.

We have continued to work systematically to address the remaining requirements. For both Dasynoc and Nilopki, the required work to manufacture additional consecutive commercial-scale batch data and the related analytical work is underway. For Nilopki, we are also preparing the documentation required to establish dose correspondence with Tasigna at the relevant dose level for a defined patient sub-population.

Following dialogue with the FDA, we have confirmed that resubmission of the NDAs for Dasynoc and Nilopki may occur independently of the cGMP status of NerPharMa. It means that the timing of our resubmissions is in our own hands. At the same time, final FDA clearance of the manufacturing facility remains necessary before either product can be approved.

Our current assessment is that the Xspray-controlled activities required for resubmission of both NDAs can be completed in time to support resubmission during the fourth quarter of 2026. We therefore reiterate our plan to resubmit both applications in Q4 2026.

The NerPharMa situation remains outside Xspray’s direct control, but we are encouraged by the progress reported by the facility. NerPharMa has previously informed the FDA that it considers its facility ready for inspection. On 5 November, we were informed that the FDA had initiated an unannounced follow-up inspection at the facility. Subject to successful resubmission, FDA review and resolution of the remaining manufacturing facility matters, our plan is to be in a position to launch both Dasynoc and Nilopki in the quarter immediately following approval.

Increasing KOL Endorsement Further Supports the Long-Term Value Proposition of Xspray´s Differentiated Platform
After the end of the quarter, we held an Investor Update in Gothenburg in connection with the ESH-iCMLf John Goldman Conference on Chronic Myeloid Leukemia. The event provided an important opportunity to place our regulatory, clinical and commercial strategy in a broader scientific context with leading CML prescribers world-wide.

At the Goldman Conference, Xspray presented two scientific posters relating to Dasynoc and Nilopki. The data support our view that HyNap-formulated products can address clinically relevant limitations of established TKI therapies. For Dasynoc, the new data further support the potential importance of lower exposure variability and the future opportunity to evaluate a lower-dose dasatinib strategy. For Nilopki, the data support the potential relevance of reducing food-related exposure effects and thereby improving predictability in everyday use.
Equally important is the work of preparing the ground for our products ahead of launch. At the Goldman Conference, our two posters generated substantial discussion and feedback from physicians treating CML. That dialogue is consistent with what our earlier U.S. market research has indicated: that physicians and patients see real value in our TKI formulations offering more predictable exposure and simpler everyday use.

The Investor Update also featured Professor Michael J. Mauro and Professor Jorge Cortes, two internationally recognized CML experts and co-authors of the poster abstracts, who joined our Chief Scientific Officer Per Andersson in a moderated expert discussion. Their participation underlined the clinical relevance of the questions addressed by our science: dose, exposure variability, pleural effusion risk, food effect, cardiovascular safety considerations and patient quality of life, through our improved formulations for long-term CML treatment.

This matters because the Xspray case is not only about reaching the next regulatory milestone. Approval remains the most important near-term value driver, but the long-term opportunity is broader. The new data strengthen our belief that Dasynoc and Nilopki may offer clinically meaningful differentiation in CML and that our HyNap technology can serve as a platform for developing improved versions of established oncology medicines.

Financing and shareholder support
In connection with this report, we have announced a financing package consisting of a rights issue and an over-allotment issue. The financing has received strong support from existing shareholders and new well-reputed investors, with subscription commitments and indications corresponding to approximately 116 percent of the rights issue. The existing loan conditions have been renegotiated into a loan facility of SEK 50 million and extended to 15 August 2028.

The purpose of the financing is aligned with our previously communicated priorities: to focus resources on value-creating milestones to support the ongoing regulatory, manufacturing and pre-commercialization of Dasynoc and Nilopki, as well as to advance the company´s development pipeline and enhance its future manufacturing capacity.

We are grateful for the continued confidence shown by our shareholders and by new investors. Their support is important as we move through the final regulatory steps and prepare the company for commercial launch.

Financial discipline and efficient execution
We continue to manage Xspray’s resources with a clear focus on value creation, launch readiness and financial discipline. During the first nine months of 2026, operating expenses decreased by 15 percent compared with the corresponding period last year. In the third quarter, cash flow from operating and investing activities improved to SEK -39.0 million, compared with SEK -47.3 million in the second quarter 2026, corresponding to a 17 percent reduction in negative cash flow.

During the quarter, we also completed a contractual repayment of SEK 50.4 million of our outstanding debt financing, reducing the Company’s outstanding debt.

These measures reflect our continued commitment to responsible financial management. We are maintaining a lean and efficient organization, while preserving the capabilities required to complete the remaining regulatory work, sustain launch readiness and continue building the scientific and commercial foundation for Dasynoc, Nilopki and the broader HyNap platform.

Positioned for the next phase
Xspray is approaching a decisive phase. The regulatory process has taken longer than expected, and we recognize the patience required from shareholders and other stakeholders. At the same time, the market potential remains unchanged. CML remains a long-duration treatment setting, physicians continue to need effective and practical therapies, and the case for improved formulations of established TKIs has continued to strengthen.

Our priorities are clear: complete the remaining work required for resubmission of Dasynoc and Nilopki in the fourth quarter, closely monitoring the resolution of the NerPharMa facility matter, maintain launch readiness, secure the financing required for execution and continue building the scientific evidence behind our differentiated product profiles.

We remain focused, realistic and forward-looking. With two lead product candidates in CML, a proprietary formulation platform, a growing body of scientific evidence and continued support from shareholders and investors, we believe Xspray is well positioned to move from late-stage regulatory execution toward commercial oncology launch.

(Press release, Xspray, NOV 6, 2026, View Source [SID1234674408])